Microtransplantation Combined With Azacytidine to Improve the Efficacy of EAML

Exclusion Criteria

• •received operation 4 weeks before randomization
• •acute promyelocytic leukemia,Myeloid sarcoma, chronic myeloid leukemia in accelerated phase and blastic phase;
• •active CNS disease, pregnancy, or other major medical or psychiatric illnesses that could compromise tolerance to this protocol
• •occurred stroke or intracranial hemorrhage within 6 months before randomization.
• •Require the use of warfarin or equivalent of vitamin K antagonists (such as phenprocoumon) anticoagulant.
• •There is clinical significance of cardiovascular disease, such as uncontrolled or symptomatic arrhythmias, congestive heart failure or myocardial infarction within 6 months before randomization, or any heart function grade 3 (moderate) or 4 (severe ) heart disease in accordance with the functional classification method of New York Heart Association (NYHA).
• •Known to have the following history: human immunodeficiency virus (HIV) or active hepatitis C virus or hepatitis B virus infection
• •Any situation processed by the PI that will be damaged to the patients safety.
• •Patients and / or authorized family member refuse to sign the consent.
• •attend other clinical researchers in 3 months.